Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2028

Conditions
Melanoma, Stage IIMelanoma Stage IIIMelanoma Stage IV
Interventions
DIAGNOSTIC_TEST

Joint ultrasonography

"Patients will undergo rheumatologic visits at baseline and scheduled follow-ups.~Rheumatologic visit procedures:~* collection of patients' anamnesis of rheumatologic diaseases.~* identification of painful and/or swollen joints and enthesis.~* evaluation of joint and enthesis pain.~* joint ultrasonography and assessment of joint structures and enthesis."

OTHER

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0

"Patients will undergo dermatologic visits at baseline and scheduled follow-ups.~Dermatologic visit procedures:~* collection of patients' oncologic anamnesis and general personal and lifestyle information.~* administration of the quality of life questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0) to assess the impact of rheumatologic adverse events on patients' quality of life."

Trial Locations (1)

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Dermatologia, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06780397 - Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients | Biotech Hunter | Biotech Hunter